Freshmedx has entered into an agreement with a Japanese partnership to co-develop, market, distribute and sell its proprietary Computerized Bioconductance Test (CB Test) in Japan.

The venture plans to enter into local development to make the non-invasive technology available to this group.

The Freshmedx CB Test is designed to evaluate suspicious lung lesions when the disease is at its most manageable stage.

Freshmedx president and CEO Steven Eror said they are heartened by the quality of Japan’s medical community and the intensity of its interest in stemming costs and bringing information forward for lung cancer patients.

"Our partnership with experienced physicians from Japan’s medical industry will allow us to help from growing at-risk populations," Eror said.